



EluPro™
Antibiotic-Eluting BioEnvelope

ENDURALIFE™
Battery Technology

**Boston
Scientific**

Protect your patient. Protect the pocket.

Protecting patients throughout the cardiac implantable electronic device (CIED) journey is critical, particularly as cardiac implantable electronic device infections are associated with additional hospital stays, higher costs, and increased mortality.¹ To protect the patient and pocket over time, Boston Scientific's Cardiac Rhythm Management portfolio combines extended device longevity and bioenvelope technology to **decrease potential reintervention**.

Fewer replacements with EnduraLife



Longest battery life across ICDs with comparable program settings.²

EnduraLife **enables fewer replacements and reduced risks** associated with replacements.^{3,4}

Reduce infection occurrence with longer-lasting devices



De novo implant infection risk is less than 1%¹⁻⁵ while replacement implant infection risk increases to 5%.^{2,6-8}

Larger-capacity devices **cut annual major complications** by 39% across Medicare and VA populations.^{9,10}

The EluPro antibiotic-eluting bioenvelope is engineered for early impact



At least **7 days** of rifampin + minocycline elution.¹¹

100% bacterial eradication.¹¹

Smooth, flexible edges require no modification to the envelope or incision for simple insertion into the pocket.^{11,12}

Regenerative healing supports long-term success



In both de novo and replacement procedures, EluPro **reduces CIED complications**, including migration and erosion. Its biomatrix **supports the formation of a healthy tissue layer** around the device, which may contribute to added stabilization.^{11,13}

The Bioenvelope demonstrated:

- 46% easier generator mobilization
- 41% easier lead mobilization
- 50% less fibrous lead entrapment
- 78% reduction in capsulectomy procedures^{11,12}

1. Lekkerkerker JC, van Nieuwkoop C, Trines SA, et al. Risk factors and time delay associated with cardiac device infections: Leiden device registry. *Heart*. 2009;95(9):715-720. doi:10.1136/hrt.2008.151985
2. Freeman JV, Torre M, Sanders P, et al. Variability in implantable cardioverter-defibrillator battery longevity. *Heart Rhythm*. 2026;23(5):1162-1171. doi:10.1016/j.hrthm.2025.05.031
3. Williams JL, Harley B, Williams G. First Demonstration of Cardiac Resynchronization Therapy Defibrillator Service Life Exceeding Patient Survival in a Heart Failure with Reduced Ejection Fraction Cohort. *J Innov Card Rhythm Manag*. 2020;11(12):4325-4332. Published 2020 Dec 15. doi:10.19102/icrm.2020.111203
4. Baddour LM, Esquer Garrigos Z, Rizwan Sohail M, et al. Update on Cardiovascular Implantable Electronic Device Infections and Their Prevention, Diagnosis, and Management: A Scientific Statement From the American Heart Association: Endorsed by the International Society for Cardiovascular Infectious Diseases. *Circulation*. 2024;149(2):e201-e216. doi:10.1161/CIR.0000000000001187
5. Wilkoff BL. How to treat and identify device infections. *Heart Rhythm*. 2007;4(11):1467-1470. doi:10.1016/j.hrthm.2007.08.007
6. Lambert CT, Tarakji KG. Cardiac implantable electronic device infection. *Cleve Clin J Med*. 2017;84(12 Suppl 3):47-53. doi:10.3949/ccjm.84.s3.05
7. El-Chami MF, Bonner M, Holbrook R, et al. Leadless pacemakers reduce risk of device-related infection: Review of the potential mechanisms. *Heart Rhythm*. 2020;17(8):1393-1397. doi:10.1016/j.hrthm.2020.03.019
8. Baddour LM, Cha YM, Wilson WR. Clinical practice. Infections of cardiovascular implantable electronic devices. *N Engl J Med*. 2012;367(9):842-849. doi:10.1056/NEJMcp1107675
9. Williams J, et al. Modeling long-term effect of biventricular defibrillator battery capacity on major complications and costs associated with replacement procedures. *Poster presented at: Heart Rhythm Society Annual Scientific Sessions*; July 2021; Boston, MA.
10. Williams J, et al. Modeling long-term effect of biventricular defibrillator battery capacity on major complications and costs associated with replacement procedures in the Veterans Health Administration. *Poster presented at: American College of Cardiology*; April 2022; Washington, DC.
11. Catanzaro JN, Christopher TJ, Issa ZF, et al. Preclinical and clinical evaluation of ECM bioenvelopes for preventing CIED pocket complications. *Front Cardiovasc Med*. 2025;12:1638929. Published 2025 Sep 12. doi:10.3389/fcvm.2025.1638929
12. Catanzaro JN, Wood MM, Kramer KB, et al. Clinical outcomes of bioenvelope use during CIED changeouts: the HEAL study. *Heart Rhythm*. 2023;20(5 Suppl):S712-S713.
13. EluPro IFU



EluPro™ Antibiotic-Eluting BioEnvelope
Indications, Safety, and Warnings
<https://qrco.de/bgqGyo>



RESONATE™ HF, RESONATE™,
RESONATE™ X4, VIGILANT™, VIGILANT™ X4,
MOMENTUM™, MOMENTUM™ X4
Indications, Safety and Warnings
<https://qrco.de/bg2DeF>



RESONATE™ HF, RESONATE™ EL, PERCIVA™ HF,
PERCIVA™, VIGILANT™ EL,
MOMENTUM™ EL Indications, Safety and Warnings
<https://qrco.de/bg2DdE>

**Boston
Scientific**
Advancing science for life™

Cardiology
300 Boston Scientific Way
Marlborough, MA 01752-1234
www.bostonscientific.com

Medical Professionals:
1.800.CARDIAC (227.3422)
Customer Service:
1.800.272.1001

Caution: Federal Law (U.S.) restricts this device to sale by or on the order of a licensed medical practitioner. For full prescribing information, including indications, contraindications, warnings, and precautions, refer to the Instructions For Use (IFU).

© 2026 Boston Scientific Corporation
or its affiliates. All rights reserved.
CRM-2515011-AA Rx Only